

Vesna Sossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1371201/publications.pdf>

Version: 2024-02-01

156
papers

10,013
citations

53794

45
h-index

36028

97
g-index

158
all docs

158
docs citations

158
times ranked

9770
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Invasive and Non-invasive Estimation of [¹¹ C]PBR28 Binding in Non-human Primates. <i>Molecular Imaging and Biology</i> , 2022, 24, 404-415.	2.6	0
2	A 4-D Iterative HYPR Denoising Operator Improves PET Image Quality. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2022, 6, 641-655.	3.7	2
3	Cortical morphology predicts placebo response in multiple sclerosis. <i>Scientific Reports</i> , 2022, 12, 732.	3.3	0
4	Dopaminergic Positron Emission Tomography Imaging in the Alpha β 5 Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1739-1748.	3.9	8
5	A Monte Carlo approach for improving transient dopamine release detection sensitivity. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 116-131.	4.3	8
6	Development and biological evaluation of [¹⁸ F]FMN3PA & [¹⁸ F]FMN3PU for leucine-rich repeat kinase 2 (LRRK2) in vivo PET imaging. <i>European Journal of Medicinal Chemistry</i> , 2021, 211, 113005.	5.5	8
7	Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. <i>Movement Disorders</i> , 2021, 36, 389-397.	3.9	13
8	Cross-validation study between the HRRT and the PET component of the SIGNA PET/MRI system with focus on neuroimaging. <i>EJNMMI Physics</i> , 2021, 8, 20.	2.7	8
9	Dynamic PET image reconstruction utilizing intrinsic data-driven HYPR4D denoising kernel. <i>Medical Physics</i> , 2021, 48, 2230-2244.	3.0	15
10	Quantitative PET in the 2020s: a roadmap. <i>Physics in Medicine and Biology</i> , 2021, 66, 06RM01.	3.0	36
11	Electron microscopy of antibody-conjugated, lutetium-177 lanthanide gold-coated nanoparticles: Proof of concept of targeted loci ¹⁸ A potential theranostic agent. <i>AIP Advances</i> , 2021, 11, 045035.	1.3	2
12	Dopamine release during psychological stress in euthymic bipolar I disorder: a Positron Emission Tomography study with [¹¹ C]raclopride. <i>Journal of Affective Disorders</i> , 2021, 295, 724-732.	4.1	0
13	FDG-PET in presymptomatic C9orf72 mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 31, 102687.	2.7	16
14	Amyloid-independent vascular contributions to cortical atrophy and cognition in a multi-center mixed cohort with low to severe small vessel disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
15	Machine learning methods for optimal prediction of motor outcome in Parkinson's disease. <i>Physica Medica</i> , 2020, 69, 233-240.	0.7	32
16	Modeling of [¹⁸ F]FEOBV Pharmacokinetics in Rat Brain. <i>Molecular Imaging and Biology</i> , 2020, 22, 931-939.	2.6	2
17	The Use of Random Forests to Identify Brain Regions on Amyloid and FDG PET Associated With MoCA Score. <i>Clinical Nuclear Medicine</i> , 2020, 45, 427-433.	1.3	12
18	Effect of Dopamine D ₂ Receptor Antagonists on [¹⁸ F]-FEOBV Binding. <i>Molecular Pharmaceutics</i> , 2020, 17, 865-872.	4.6	3

#	ARTICLE	IF	CITATIONS
19	Novel data-driven, equation-free method captures spatio-temporal patterns of neurodegeneration in Parkinson's disease: Application of dynamic mode decomposition to PET. <i>NeuroImage: Clinical</i> , 2020, 25, 102150.	2.7	4
20	Detection of transient neurotransmitter response using personalized neural networks. <i>Physics in Medicine and Biology</i> , 2020, 65, 235004.	3.0	4
21	Use of Generative Disease Models for Analysis and Selection of Radiomic Features in PET. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 178-191.	3.7	9
22	Optimized machine learning methods for prediction of cognitive outcome in Parkinson's disease. <i>Computers in Biology and Medicine</i> , 2019, 111, 103347.	7.0	37
23	Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1891-1900.	3.9	99
24	Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations. <i>NeuroImage: Clinical</i> , 2019, 23, 101856.	2.7	21
25	Artificial Neural Network-Based Prediction of Outcome in Parkinson's Disease Patients Using DaTscan SPECT Imaging Features. <i>Molecular Imaging and Biology</i> , 2019, 21, 1165-1173.	2.6	29
26	Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 301-313.	2.8	89
27	Imaging in Neurodegeneration: Movement Disorders. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2019, 3, 262-274.	3.7	4
28	Cerebral Amyloid- β^2 Deposition Is Associated with Impaired Gait Speed and Lower Extremity Function. <i>Journal of Alzheimer's Disease</i> , 2019, 71, S41-S49.	2.6	17
29	Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. <i>Brain</i> , 2019, 142, 512-525.	7.6	194
30	A Monte Carlo approach for boosting transient dopamine release detection sensitivity. , 2019, , .		0
31	Denosing and DA release: application of the 4D denoised reconstruction HYPR4D-K-OSEM. , 2019, , .		0
32	The Use of Random Forests to Classify Amyloid Brain PET. <i>Clinical Nuclear Medicine</i> , 2019, 44, 784-788.	1.3	15
33	Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons. <i>Journal of Parkinson's Disease</i> , 2019, 9, 121-139.	2.8	17
34	Cerebral serotonin transporter measurements with [¹¹ C]DASB: A review on acquisition and preprocessing across 21 PET centres. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 210-222.	4.3	25
35	Synthesis and targeting of gold-coated ¹⁷⁷ Lu-containing lanthanide phosphate nanoparticles: A potential theranostic agent for pulmonary metastatic disease. <i>APL Bioengineering</i> , 2018, 2, 016101.	6.2	19
36	The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. <i>Lancet Neurology</i> , The, 2018, 17, 309-316.	10.2	57

#	ARTICLE	IF	CITATIONS
37	A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR. <i>International Journal of Neuropsychopharmacology</i> , 2018, 21, 108-113.	2.1	10
38	Performance of a PET Insert for High-Resolution Small-Animal PET/MRI at 7 Tesla. <i>Journal of Nuclear Medicine</i> , 2018, 59, 536-542.	5.0	49
39	Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. <i>PLoS ONE</i> , 2018, 13, e0206607.	2.5	14
40	Advances in PET Methodology. <i>International Review of Neurobiology</i> , 2018, 141, 3-30.	2.0	7
41	Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study. <i>Movement Disorders</i> , 2018, 33, 1945-1950.	3.9	37
42	Denoising and DA release: effect of denoising on the ability to identify voxel-level neurophysiological response. , 2018, , .		2
43	Investigation of serotonergic Parkinson's disease-related covariance pattern using [11C]-DASB/PET. <i>NeuroImage: Clinical</i> , 2018, 19, 652-660.	2.7	23
44	PBB3 binding in a patient with corticobasal syndrome. <i>Movement Disorders</i> , 2018, 33, 1359-1360.	3.9	7
45	PET Image Reconstruction and Deformable Motion Correction Using Unorganized Point Clouds. <i>IEEE Transactions on Medical Imaging</i> , 2017, 36, 1263-1275.	8.9	10
46	Manganese concentration mapping in the rat brain with MRI, PET, and autoradiography. <i>Medical Physics</i> , 2017, 44, 4056-4067.	3.0	5
47	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. <i>Annals of Neurology</i> , 2017, 81, 46-57.	5.3	72
48	PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins. <i>Movement Disorders</i> , 2017, 32, 1016-1024.	3.9	62
49	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. <i>Lancet Neurology</i> , The, 2017, 16, 351-359.	10.2	96
50	188Re image performance assessment using small animal multi-pinhole SPECT/PET/CT system. <i>Physica Medica</i> , 2017, 33, 26-37.	0.7	12
51	<i>DNAJC12</i> and dopa-responsive nonprogressive parkinsonism. <i>Annals of Neurology</i> , 2017, 82, 640-646.	5.3	60
52	Improved prediction of outcome in Parkinson's disease using radiomics analysis of longitudinal DAT SPECT images. <i>NeuroImage: Clinical</i> , 2017, 16, 539-544.	2.7	76
53	Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 57, 248.e7-248.e12.	3.1	83
54	Associations between cerebral amyloid and changes in cognitive function and falls risk in subcortical ischemic vascular cognitive impairment. <i>BMC Geriatrics</i> , 2017, 17, 133.	2.7	6

#	ARTICLE	IF	CITATIONS
55	Incorporating HYPR de-noising within iterative PET reconstruction (HYPR-OSEM). Physics in Medicine and Biology, 2017, 62, 6666-6687.	3.0	19
56	¹⁸ F-5-Fluoroaminosuberic Acid as a Potential Tracer to Gauge Oxidative Stress in Breast Cancer Models. Journal of Nuclear Medicine, 2017, 58, 367-373.	5.0	36
57	Data Acquisition for a Preclinical MR Compatible PET Insert Using the OpenPET Platform. IEEE Transactions on Radiation and Plasma Medical Sciences, 2017, 1, 495-504.	3.7	3
58	Interpreting ¹ DTBZ binding data in rodent: Inherent variability and compensation. Synapse, 2016, 70, 147-152.	1.2	6
59	A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. Movement Disorders, 2016, 31, 405-409.	3.9	14
60	Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress. Scientific Reports, 2016, 6, 18537.	3.3	1
61	Exploring the use of shape and texture descriptors of positron emission tomography tracer distribution in imaging studies of neurodegenerative disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1122-1134.	4.3	15
62	Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments. NeuroImage: Clinical, 2016, 12, e1-e9.	2.7	59
63	Reply to letter to the editor: Is there anything more to learn from SWEDD?. Movement Disorders, 2016, 31, 1426-1428.	3.9	0
64	First Results From a High-Resolution Small Animal SiPM PET Insert for PET/MR Imaging at 7T. IEEE Transactions on Nuclear Science, 2016, 63, 2424-2433.	2.0	45
65	Development of a digital unrestrained mouse phantom with non-periodic deformable motion. , 2015, , .		2
66	Exploring the effects of coexisting amyloid in subcortical vascular cognitive impairment. BMC Neurology, 2015, 15, 197.	1.8	9
67	Characterization of a Small Animal PET Detector Block Incorporating a Digital Photon Counter Array. IEEE Transactions on Nuclear Science, 2015, 62, 732-739.	2.0	4
68	[¹¹ C]PBR28 PET Imaging is Sensitive to Neuroinflammation in the Aged Rat. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1331-1338.	4.3	26
69	Development of a PET Scanner for Simultaneously Imaging Small Animals with MRI and PET. Sensors, 2014, 14, 14654-14671.	3.8	21
70	Performance Assessment of a Preclinical PET Scanner with Pinhole Collimation by Comparison to a Coincidence-Based Small-Animal PET Scanner. Journal of Nuclear Medicine, 2014, 55, 1368-1374.	5.0	36
71	In vivo dopaminergic and serotonergic dysfunction in <i>DCTN1</i> gene mutation carriers. Movement Disorders, 2014, 29, 1197-1201.	3.9	15
72	Behavioral Deficits and Striatal DA Signaling in LRRK2 p.G2019S Transgenic Rats: A Multimodal Investigation Including PET Neuroimaging. Journal of Parkinson's Disease, 2014, 4, 483-498.	2.8	32

#	ARTICLE	IF	CITATIONS
73	A simple route to [11C]N-Me labeling of aminosuberic acid for proof of feasibility imaging of the xCa ²⁺ transporter. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5512-5515.	2.2	2
74	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. Parkinsonism and Related Disorders, 2014, 20, 1129-1134.	2.2	6
75	Pixelated Geiger-Mode Avalanche Photo-Diode Characterization Through Dark Current Measurement. IEEE Transactions on Nuclear Science, 2014, 61, 1369-1375.	2.0	4
76	Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. Movement Disorders, 2014, 29, 1684-1687.	3.9	20
77	Evaluation of performance and stability of an MR compatible PET detector. , 2014, , .		2
78	PET image reconstruction with correction for non-periodic deformable motion!. , 2014, , .		1
79	Texture and shape analysis on high and low spatial resolution emission images. , 2014, , .		6
80	Feasibility of using geometric descriptors of tracer distribution for disease assessment. , 2014, , .		0
81	Design and Performance of a Resistor Multiplexing Readout Circuit for a SiPM Detector. IEEE Transactions on Nuclear Science, 2013, 60, 1541-1549.	2.0	87
82	Novel spatial analysis method for PET images using 3D moment invariants: Applications to Parkinson's disease. NeuroImage, 2013, 68, 11-21.	4.2	18
83	A PET detector interface board and slow control system based on the Raspberry Pi²®</sup>. , 2013, , .		6
84	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology, 2013, 81, 1322-1331.	1.1	60
85	Measurement of energy and timing resolution of very highly pixellated LYSO crystal blocks with multiplexed SiPM readout for use in a small animal PET/MR insert. , 2013, , .		5
86	<i>In-vivo</i> Measurement of LDOPA Uptake, Dopamine Reserve and Turnover in the Rat Brain Using [¹⁸ F]FDOPA PET. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 59-66.	4.3	33
87	The Nature of Progression in Parkinson's Disease: An Application of Non-Linear, Multivariate, Longitudinal Random Effects Modelling. PLoS ONE, 2013, 8, e76595.	2.5	30
88	Resolution modeling in PET imaging: Theory, practice, benefits, and pitfalls. , 2013, 40, 064301.		1
89	Abnormal Metabolic Brain Networks in a Nonhuman Primate Model of Parkinsonism. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 633-642.	4.3	32
90	In Vivo Dopamine Transporter Imaging in a Unilateral 6-Hydroxydopamine Rat Model of Parkinson Disease Using ¹¹ C-Methylphenidate PET. Journal of Nuclear Medicine, 2012, 53, 813-822.	5.0	15

#	ARTICLE	IF	CITATIONS
91	Application of HDMIÂ® cables as an MRI compatible single cable solution for Readout and power supply of SiPM based PET detectors. , 2012, , .		10
92	Estimation of NECR, scatter fraction, and sensitivity of a new MR compatible small animal PET insert based on Monte-Carlo simulations. , 2012, , .		0
93	Analytical modeling and implementation of detector response for fully 3D computer simulation and image reconstruction of an MRI compatible PET insert with a dual-layer offset crystal design. , 2012, , .		2
94	NEMA NU 4-2008 Comparison of Preclinical PET Imaging Systems. Journal of Nuclear Medicine, 2012, 53, 1300-1309.	5.0	191
95	Irrational Choice under Uncertainty Correlates with Lower Striatal D _{2/3} Receptor Binding in Rats. Journal of Neuroscience, 2012, 32, 15450-15457.	3.6	69
96	Evaluation of very highly pixellated crystal blocks with SiPM readout as candidates for PET/MR detectors in a small animal PET insert. , 2012, , .		7
97	Evaluation of High Density Pixellated Crystal Blocks With SiPM Readout as Candidates for PET/MR Detectors in a Small Animal PET Insert. IEEE Transactions on Nuclear Science, 2012, 59, 1791-1797.	2.0	28
98	Imaging striatal dopaminergic function in <i>Phospholipase A2 Group VI</i> -related parkinsonism. Movement Disorders, 2012, 27, 1698-1699.	3.9	14
99	Fully-automated segmentation of the striatum in the PET/MR images using data fusion. , 2012, , .		1
100	In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [¹¹ C]methylphenidate and PET. NeuroImage, 2012, 59, 2413-2422.	4.2	19
101	Imaging DA release in a rat model of L-DOPA-induced dyskinesias: A longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA. NeuroImage, 2012, 63, 423-433.	4.2	12
102	Scanning rats on the high resolution research tomograph (HRRT): A comparison study with a dedicated micro-PET. Medical Physics, 2012, 39, 5073-5083.	3.0	17
103	Technical performance evaluation of a human brain PET/MRI system. European Radiology, 2012, 22, 1776-1788.	4.5	140
104	Functional neuroimaging in Parkinson's disease. Expert Opinion on Medical Diagnostics, 2011, 5, 109-120.	1.6	7
105	Frame-to-frame image realignment assessment tool for dynamic brain positron emission tomography. Medical Physics, 2011, 38, 773-781.	3.0	10
106	Advances in imaging in Parkinson's disease. Lancet Neurology, The, 2011, 10, 987-1001.	10.2	99
107	Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Annals of Neurology, 2011, 69, 803-810.	5.3	197
108	Evaluation of high density pixilated crystal blocks with SiPM readout as candidates for PET/MR detectors in a small animal PET insert. , 2011, , .		9

#	ARTICLE	IF	CITATIONS
109	PET image reconstruction and motion correction using direct backprojection on point grids and clouds. , 2011, , .		1
110	Simulation guided optimization of Dual Layer Offset detector design for use in small animal PET. , 2011, , .		7
111	Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. <i>Brain</i> , 2011, 134, 3290-3298.	7.6	133
112	Dorsal Striatal D ₂ -Like Receptor Availability Covaries with Sensitivity to Positive Reinforcement during Discrimination Learning. <i>Journal of Neuroscience</i> , 2011, 31, 7291-7299.	3.6	81
113	Noninvasive Nuclear Imaging Enables the In Vivo Quantification of Striatal Dopamine Receptor Expression and Raclopride Affinity in Mice. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1133-1141.	5.0	29
114	Brain serotonin-2 receptors in acute mania. <i>British Journal of Psychiatry</i> , 2010, 196, 47-51.	2.8	21
115	Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2364-2370.	6.4	34
116	Dopamine turnover increases in asymptomatic <i>LRRK2</i> mutations carriers. <i>Movement Disorders</i> , 2010, 25, 2717-2723.	3.9	103
117	Dopamine transporter PET in normal aging: Dopamine transporter decline and its possible role in preservation of motor function. <i>Synapse</i> , 2010, 64, 146-151.	1.2	46
118	Positron emission tomography kinetic modeling algorithms for small animal dopaminergic system imaging. <i>Synapse</i> , 2010, 64, 200-208.	1.2	20
119	Scanning rodents on the High Resolution Research Tomograph (HRRT) with point spread function reconstruction: A feasibility study. , 2010, , .		1
120	Effect of electroconvulsive therapy on brain 5-HT ₂ receptors in major depression. <i>British Journal of Psychiatry</i> , 2010, 196, 474-479.	2.8	76
121	Trials of neuroprotective therapies for Parkinson's disease: Problems and limitations. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 365-369.	2.2	44
122	A Scatter Calibration Technique for Dynamic Brain Imaging in High Resolution PET. <i>IEEE Transactions on Nuclear Science</i> , 2010, 57, 225-233.	2.0	13
123	Quality control protocol for frame-to-frame PET motion correction. , 2009, , .		1
124	Visualizing vesicular dopamine dynamics in Parkinson's disease. <i>Synapse</i> , 2009, 63, 713-716.	1.2	50
125	Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's disease: an <i>in vivo</i> imaging study. <i>Journal of Neurochemistry</i> , 2009, 109, 85-92.	3.9	50
126	An Analytical Scatter Correction for Singles-Mode Transmission Data in PET. <i>IEEE Transactions on Medical Imaging</i> , 2008, 27, 402-412.	8.9	15

#	ARTICLE	IF	CITATIONS
127	Accurate Event-Driven Motion Compensation in High-Resolution PET Incorporating Scattered and Random Events. IEEE Transactions on Medical Imaging, 2008, 27, 1018-1033.	8.9	132
128	Impact of Contamination from Scattered Photons in Singles-Mode Transmission Data on Quantitative Small-Animal PET Imaging. Journal of Nuclear Medicine, 2008, 49, 1852-1861.	5.0	7
129	Latest advance in the scatter calibration and combining the scatter calibration with a practical scatter and random approximation technique for dynamic brain imaging in high resolution PET. , 2008, , .		1
130	System matrix modelling of externally tracked motion. Nuclear Medicine Communications, 2008, 29, 574-581.	1.1	29
131	A Global and a segmented plane scatter calibration: improving the quantitative accuracy of frames with high random fraction and/or low number of counts in dynamic high resolution PET brain imaging. , 2007, , .		2
132	Cutting-Edge Brain Imaging with Positron Emission Tomography. Neuroimaging Clinics of North America, 2007, 17, 427-440.	1.0	7
133	Cutting-Edge Brain Imaging with Positron Emission Tomography. PET Clinics, 2007, 2, 91-104.	3.0	3
134	In Vivo Measurement of Density and Affinity of the Monoamine Vesicular Transporter in a Unilateral 6-Hydroxydopamine Rat Model of PD. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1407-1415.	4.3	40
135	Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1533-1539.	4.3	1,840
136	Investigation of Subject Motion Encountered During a Typical Positron Emission Tomography Scan. , 2006, , .		13
137	Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain, 2006, 129, 1050-1058.	7.6	76
138	PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain, 2005, 128, 2777-2785.	7.6	242
139	Positron emission tomography after fetal transplantation in Huntington's disease. Annals of Neurology, 2005, 58, 331-337.	5.3	57
140	The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET [®] R4: a phantom study. Physics in Medicine and Biology, 2005, 50, 2859-2869.	3.0	12
141	Changes of Dopamine Turnover in the Progression of Parkinson's Disease as Measured by Positron Emission Tomography: Their Relation to Disease-Compensatory Mechanisms. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 869-876.	4.3	81
142	Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain, 2004, 127, 2747-2754.	7.6	361
143	Lack of Regional Selectivity During the Progression of Parkinson Disease. Archives of Neurology, 2004, 61, 1920-5.	4.5	47
144	A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Annals of Neurology, 2003, 54, 403-414.	5.3	1,450

#	ARTICLE	IF	CITATIONS
145	Age and severity of nigrostriatal damage at onset of Parkinson's disease. <i>Synapse</i> , 2003, 47, 152-158.	1.2	33
146	[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. <i>Brain</i> , 2003, 126, 2648-2655.	7.6	63
147	PET Study of [18F]6-Fluoro-l-Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium. <i>American Journal of Psychiatry</i> , 2002, 159, 768-774.	7.2	123
148	PET Study of the Effects of Valproate on Dopamine D2Receptors in Neuroleptic- and Mood-Stabilizer-Naive Patients With Nonpsychotic Mania. <i>American Journal of Psychiatry</i> , 2002, 159, 1718-1723.	7.2	86
149	Dopamine release in human ventral striatum and expectation of reward. <i>Behavioural Brain Research</i> , 2002, 136, 359-363.	2.2	303
150	Increase in Dopamine Turnover Occurs Early in Parkinson's Disease: Evidence from a New Modeling Approach to PET 18F-Fluorodopa Data. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002, 22, 232-239.	4.3	117
151	PET performance measurements using the NEMA NU 2-2001 standard. <i>Journal of Nuclear Medicine</i> , 2002, 43, 1398-409.	5.0	130
152	Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease. <i>Science</i> , 2001, 293, 1164-1166.	12.6	885
153	A Reversible Tracer Analysis Approach to the Study of Effective Dopamine Turnover. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 469-476.	4.3	67
154	Apomorphine-Induced Changes in Synaptic Dopamine Levels: Positron Emission Tomography Evidence for Presynaptic Inhibition. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001, 21, 1151-1159.	4.3	52
155	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. <i>Annals of Neurology</i> , 2001, 49, 298-303.	5.3	85
156	Basal Ganglia Studies with 3D Acquisition and 2D Reconstruction on a Retractable Septa PET Scanner. <i>Journal of Computer Assisted Tomography</i> , 1994, 18, 1004-1009.	0.9	4